The feasibility of CCK2R targeting with radiolabeled peptides derived from the natural ligands minigastrin (MG) and cholecystokinin has already been proven for patients with advanced MTC as well as other CCK2R-related malignancies [8,9]. This evidence concerns the gene CCKBR and medullary thyroid gland carcinoma.